Table 4.
Multivariate analysis on 117 lung neuroendocrine tumours showed mutation in RB1 and gain in TERT as independent prognostic markers of poor prognosis
| Covariate | Univariate hazard ratio | 95% CI | Multivariate hazard ratio | 95% CI | p‐Value * |
|---|---|---|---|---|---|
| Histotype = LCNEC | 2.45 | 0.91–6.61 | 3.84 | 1.28–11.52 | 0.016 |
| Histotype = SCLC | 6.53 | 2.45–17.40 | 5.41 | 1.55–18.93 | 0.0082 |
| Stage = III | 12.47 | 4.88–31.88 | 3.90 | 1.40–10.87 | 0.0091 |
| Stage = IV | 19.45 | 5.60–67.49 | 9.14 | 3.18–26.29 | <0.0001 |
| RB1: mutation† | 3.29 | 0.96–11.30 | 5.76 | 2.14–15.50 | 0.0005 |
| TERT: gain† | 1.55 | 0.80–3.02 | 2.55 | 1.19–5.44 | 0.016 |
CI, confidence interval; LCNEC, large‐cell neuroendocrine carcinoma; SCLC, small‐cell lung cancer.
Cox proportional‐hazards regression analysis. Selection of the best model was performed with the ‘forward’ algorithm.
Univariate analysis of RB1 mutation and TERT copy gain includes only atypical carcinoids, LCNECs, and SCLCs. Typical carcinoid cases were excluded from univariate analysis of molecular alterations, given that their features (i.e. no death from disease after long follow‐up) would have represented a confounding effect on analysis of the impact of molecular markers on the rest of the series.